{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:43:49Z","timestamp":1793227429466,"version":"4.5.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017618","name":"Division of Diabetes, Endocrinology, and Metabolic Diseases","doi-asserted-by":"publisher","award":["K23DK131363"],"award-info":[{"award-number":["K23DK131363"]}],"id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017618","name":"Division of Diabetes, Endocrinology, and Metabolic Diseases","doi-asserted-by":"publisher","award":["K12DK133995"],"award-info":[{"award-number":["K12DK133995"]}],"id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI042288"],"award-info":[{"award-number":["P01AI042288"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40265-025-02150-8","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T08:24:17Z","timestamp":1738052657000},"page":"457-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Emerging Immunotherapies for Disease Modification of Type 1 Diabetes"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-4558","authenticated-orcid":false,"given":"Timothy P.","family":"Foster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany S.","family":"Bruggeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"issue":"9","key":"2150_CR1","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.cmet.2023.06.018","volume":"35","author":"MA Atkinson","year":"2023","unstructured":"Atkinson MA, Mirmira RG. The pathogenic \u201csymphony\u201d in type 1 diabetes: a disorder of the immune system, \u03b2 cells, and exocrine pancreas. Cell Metab. 2023;35(9):1500\u201318.","journal-title":"Cell Metab"},{"key":"2150_CR2","unstructured":"Lawrence JM, Casagrande SS, Herman WH, Wexler DJ, Cefalu WT, editors. Diabetes in America [online]. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases; 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK597413\/."},{"key":"2150_CR3","volume-title":"Immunotherapy of type 1 diabetes","author":"D Andreani","year":"1989","unstructured":"Andreani D, Kolb H, Pozzilli P. Immunotherapy of type 1 diabetes. New York: Wiley; 1989."},{"issue":"9","key":"2150_CR4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00125-023-05955-y","volume":"66","author":"AM Luckett","year":"2023","unstructured":"Luckett AM, Weedon MN, Hawkes G, Leslie RD, Oram RA, Grant SFA. Utility of genetic risk scores in type 1 diabetes. Diabetologia. 2023;66(9):1589\u2013600.","journal-title":"Diabetologia"},{"issue":"23","key":"2150_CR5","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1001\/jama.2013.6285","volume":"309","author":"AG Ziegler","year":"2013","unstructured":"Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473\u20139.","journal-title":"JAMA"},{"issue":"21","key":"2150_CR6","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1056\/NEJM198605223142106","volume":"314","author":"GS Eisenbarth","year":"1986","unstructured":"Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986;314(21):1360\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"2150_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.2337\/dbi24-0019","volume":"73","author":"C Evans-Molina","year":"2024","unstructured":"Evans-Molina C, Oram RA. A golden hour and golden opportunity for \u03b2-cell preservation. Diabetes. 2024;73(6):834\u20136.","journal-title":"Diabetes"},{"issue":"7892","key":"2150_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(74)90140-8","volume":"2","author":"GF Bottazzo","year":"1974","unstructured":"Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. 1974;2(7892):1279\u201383.","journal-title":"Lancet"},{"issue":"5","key":"2150_CR9","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.2337\/db15-1615","volume":"65","author":"P Leete","year":"2016","unstructured":"Leete P, Willcox A, Krogvold L, Dahl-J\u00f8rgensen K, Foulis AK, Richardson SJ, et al. Differential insulitic profiles determine the extent of \u03b2-cell destruction and the age at onset of type 1 diabetes. Diabetes. 2016;65(5):1362\u20139.","journal-title":"Diabetes"},{"issue":"1","key":"2150_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1172\/JCI0213605","volume":"109","author":"A Kukreja","year":"2002","unstructured":"Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002;109(1):131\u201340.","journal-title":"J Clin Invest"},{"issue":"13","key":"2150_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/jama.1957.02980130015004","volume":"164","author":"E Witebsky","year":"1957","unstructured":"Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW. Chronic thyroiditis and autoimmunization. J Am Med Assoc. 1957;164(13):1439\u201347.","journal-title":"J Am Med Assoc"},{"issue":"5","key":"2150_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/imcb.12437","volume":"99","author":"AE Wiedeman","year":"2021","unstructured":"Wiedeman AE, Speake C, Long SA. The many faces of islet antigen-specific CD8 T cells: clues to clinical outcome in type 1 diabetes. Immunol Cell Biol. 2021;99(5):475\u201385.","journal-title":"Immunol Cell Biol"},{"key":"2150_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.606434","volume":"11","author":"C Bender","year":"2020","unstructured":"Bender C, Rajendran S, von Herrath MG. New insights into the role of autoreactive CD8 T cells and cytokines in human type 1 diabetes. Front Endocrinol (Lausanne). 2020;11: 606434.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"3","key":"2150_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/pedi.12597","volume":"19","author":"MJ Redondo","year":"2018","unstructured":"Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. Pediatr Diabetes. 2018;19(3):346\u201353.","journal-title":"Pediatr Diabetes"},{"key":"2150_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.mam.2014.12.004","volume":"42","author":"MP Morran","year":"2015","unstructured":"Morran MP, Vonberg A, Khadra A, Pietropaolo M. Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med. 2015;42:42\u201360.","journal-title":"Mol Aspects Med"},{"key":"2150_CR16","doi-asserted-by":"publisher","first-page":"1326711","DOI":"10.3389\/fimmu.2023.1326711","volume":"14","author":"JRN Lemos","year":"2023","unstructured":"Lemos JRN, Hirani K, von Herrath M. Immunological and virological triggers of type 1 diabetes: insights and implications. Front Immunol. 2023;14:1326711.","journal-title":"Front Immunol"},{"issue":"8","key":"2150_CR17","doi-asserted-by":"publisher","DOI":"10.2174\/1573399817666210503133747","volume":"17","author":"AG Abela","year":"2021","unstructured":"Abela AG, Fava S. Why is the incidence of type 1 diabetes increasing? Curr Diabetes Rev. 2021;17(8): e030521193110.","journal-title":"Curr Diabetes Rev"},{"issue":"11","key":"2150_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41574-019-0254-y","volume":"15","author":"J Ilonen","year":"2019","unstructured":"Ilonen J, Lempainen J, Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol. 2019;15(11):635\u201350.","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"2150_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nri2787","volume":"10","author":"A Lehuen","year":"2010","unstructured":"Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol. 2010;10(7):501\u201313.","journal-title":"Nat Rev Immunol"},{"key":"2150_CR20","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","volume":"3","author":"A Katsarou","year":"2017","unstructured":"Katsarou A, Gudbj\u00f6rnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016.","journal-title":"Nat Rev Dis Primers"},{"issue":"7293","key":"2150_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/nature08933","volume":"464","author":"JA Bluestone","year":"2010","unstructured":"Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293\u2013300.","journal-title":"Nature"},{"issue":"4","key":"2150_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s00125-021-05647-5","volume":"65","author":"M So","year":"2022","unstructured":"So M, O\u2019Rourke C, Ylescupidez A, Bahnson HT, Steck AK, Wentworth JM, et al. Characterising the age-dependent effects of risk factors on type 1 diabetes progression. Diabetologia. 2022;65(4):684\u201394.","journal-title":"Diabetologia"},{"issue":"11","key":"2150_CR23","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.2337\/dc21-0770","volume":"44","author":"RD Leslie","year":"2021","unstructured":"Leslie RD, Evans-Molina C, Freund-Brown J, Buzzetti R, Dabelea D, Gillespie KM, et al. Adult-onset type 1 diabetes: current understanding and challenges. Diabetes Care. 2021;44(11):2449\u201356.","journal-title":"Diabetes Care"},{"issue":"11","key":"2150_CR24","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.7326\/M23-1707","volume":"176","author":"M Fang","year":"2023","unstructured":"Fang M, Wang D, Echouffo-Tcheugui JB, Selvin E. Age at diagnosis in US adults with type 1 diabetes. Ann Intern Med. 2023;176(11):1567\u20138.","journal-title":"Ann Intern Med"},{"issue":"11","key":"2150_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11892-018-1083-4","volume":"18","author":"P Leete","year":"2018","unstructured":"Leete P, Mallone R, Richardson SJ, Sosenko JM, Redondo MJ, Evans-Molina C. The effect of age on the progression and severity of type 1 diabetes: potential effects on disease mechanisms. Curr Diab Rep. 2018;18(11):115.","journal-title":"Curr Diab Rep"},{"issue":"9","key":"2150_CR26","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.2337\/dc24-0573","volume":"47","author":"LP Zhao","year":"2024","unstructured":"Zhao LP, Papadopoulos GK, Skyler JS, Parikh HM, Kwok WW, Bondinas GP, et al. Oral insulin delay of stage 3 type 1 diabetes revisited in HLA DR4-DQ8 participants in the TrialNet oral insulin prevention trial (TN07). Diabetes Care. 2024;47(9):1608\u201316.","journal-title":"Diabetes Care"},{"issue":"2","key":"2150_CR27","first-page":"186","volume":"11","author":"EC Kennedy","year":"2024","unstructured":"Kennedy EC, Hawkes CP. Approaches to measuring beta cell reserve and defining partial clinical remission in paediatric type 1 diabetes. Children (Basel). 2024;11(2):186.","journal-title":"Children (Basel)."},{"issue":"12","key":"2150_CR28","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1089\/dia.2020.0305","volume":"22","author":"LM Jacobsen","year":"2020","unstructured":"Jacobsen LM, Bundy BN, Greco MN, Schatz DA, Atkinson MA, Brusko TM, et al. Comparing beta cell preservation across clinical trials in recent-onset type 1 diabetes. Diabetes Technol Ther. 2020;22(12):948\u201353.","journal-title":"Diabetes Technol Ther"},{"issue":"12","key":"2150_CR29","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2337\/dc17-1624","volume":"40","author":"G Agiostratidou","year":"2017","unstructured":"Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, et al. Standardizing clinically meaningful outcome measures beyond HbA1c. Diabetes Care. 2017;40(12):1622\u201330.","journal-title":"Diabetes Care"},{"issue":"6","key":"2150_CR30","first-page":"271","volume":"2","author":"GS Eisenbarth","year":"1985","unstructured":"Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T, et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res. 1985;2(6):271\u20136.","journal-title":"Diabetes Res"},{"issue":"10","key":"2150_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJM198809083191002","volume":"319","author":"J Silverstein","year":"1988","unstructured":"Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med. 1988;319(10):599\u2013604.","journal-title":"N Engl J Med"},{"issue":"8499","key":"2150_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0140-6736(86)91943-4","volume":"2","author":"G Feutren","year":"1986","unstructured":"Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet. 1986;2(8499):119\u201324.","journal-title":"Lancet"},{"key":"2150_CR33","unstructured":"ATGAM (lymphocyte immune globulin, anti-thymocyte globulin [equine]) [package insert]. New York: Pfizer Inc.; 1981."},{"issue":"7","key":"2150_CR34","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","volume":"21","author":"M Mohty","year":"2007","unstructured":"Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387\u201394.","journal-title":"Leukemia"},{"issue":"4425","key":"2150_CR35","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1126\/science.388619","volume":"206","author":"AA Like","year":"1979","unstructured":"Like AA, Rossini AA, Guberski DL, Appel MC, Williams RM. Spontaneous diabetes mellitus: reversal and prevention in the BB\/W rat with antiserum to rat lymphocytes. Science. 1979;206(4425):1421\u20133.","journal-title":"Science"},{"issue":"10","key":"2150_CR36","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/BF00274528","volume":"32","author":"EF Lampeter","year":"1989","unstructured":"Lampeter EF, Signore A, Gale EA, Pozzilli P. Lessons from the NOD mouse for the pathogenesis and immunotherapy of human type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1989;32(10):703\u20138.","journal-title":"Diabetologia"},{"issue":"4","key":"2150_CR37","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-8587(13)70065-2","volume":"1","author":"SE Gitelman","year":"2013","unstructured":"Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013;1(4):306\u201316.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2150_CR38","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00125-016-3917-4","volume":"59","author":"SE Gitelman","year":"2016","unstructured":"Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, et al. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia. 2016;59(6):1153\u201361.","journal-title":"Diabetologia"},{"issue":"6","key":"2150_CR39","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2337\/db19-0057","volume":"68","author":"MJ Haller","year":"2019","unstructured":"Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, et al. Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA. Diabetes. 2019;68(6):1267\u201376.","journal-title":"Diabetes"},{"issue":"2","key":"2150_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2337\/dc23-1750","volume":"47","author":"TP Foster","year":"2024","unstructured":"Foster TP, Jacobsen LM, Bruggeman B, Salmon C, Hosford J, Chen A, et al. Low-dose antithymocyte globulin: a pragmatic approach to treating stage 2 type 1 diabetes. Diabetes Care. 2024;47(2):285\u20139.","journal-title":"Diabetes Care"},{"key":"2150_CR41","unstructured":"ClinicalTrials.gov USNLoM. STOP-T1D Low-Dose (ATG) (TN28). Available from: https:\/\/clinicaltrials.gov\/study\/NCT04291703. Accessed 6 Nov 2024."},{"issue":"1","key":"2150_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2150_CR43","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1172\/JCI82267","volume":"125","author":"G Couvrat-Desvergnes","year":"2015","unstructured":"Couvrat-Desvergnes G, Salama A, Le Berre L, Evanno G, Viklicky O, Hruba P, et al. Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival. J Clin Invest. 2015;125(12):4655\u201365.","journal-title":"J Clin Invest"},{"key":"2150_CR44","unstructured":"Registry ANZCT. A phase I randomised, double-blinded, placebo-controlled, single ascending dose adaptive design study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous SAB-142. https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12623001089628. Accessed 7 Nov 2024."},{"issue":"5","key":"2150_CR45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-023-01847-y","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Teplizumab: first approval. Drugs. 2023;83(5):439\u201345.","journal-title":"Drugs"},{"issue":"5","key":"2150_CR46","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/00007890-199909150-00003","volume":"68","author":"ES Woodle","year":"1999","unstructured":"Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O\u2019Laughlin R, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 1999;68(5):608\u201316.","journal-title":"Transplantation"},{"issue":"10","key":"2150_CR47","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1002\/eji.201040485","volume":"40","author":"V Ablamunits","year":"2010","unstructured":"Ablamunits V, Bisikirska B, Herold KC. Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010;40(10):2891\u2013901.","journal-title":"Eur J Immunol"},{"issue":"22","key":"2150_CR48","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1056\/NEJMoa012864","volume":"346","author":"KC Herold","year":"2002","unstructured":"Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1692\u20138.","journal-title":"N Engl J Med"},{"issue":"25","key":"2150_CR49","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1056\/NEJMoa043980","volume":"352","author":"B Keymeulen","year":"2005","unstructured":"Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352(25):2598\u2013608.","journal-title":"N Engl J Med"},{"issue":"10","key":"2150_CR50","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.2337\/dc13-0327","volume":"37","author":"R Aronson","year":"2014","unstructured":"Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014;37(10):2746\u201354.","journal-title":"Diabetes Care"},{"issue":"10","key":"2150_CR51","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.2337\/dc23-0675","volume":"46","author":"KC Herold","year":"2023","unstructured":"Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL. Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves \u03b2-cell function. Diabetes Care. 2023;46(10):1848\u201356.","journal-title":"Diabetes Care"},{"key":"2150_CR52","doi-asserted-by":"crossref","unstructured":"Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13(583):eabc8980.","DOI":"10.1126\/scitranslmed.abc8980"},{"issue":"23","key":"2150_CR53","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","volume":"389","author":"EL Ramos","year":"2023","unstructured":"Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, et al. Teplizumab and \u03b2-cell function in newly diagnosed type 1 diabetes. N Engl J Med. 2023;389(23):2151\u201361.","journal-title":"N Engl J Med"},{"key":"2150_CR54","unstructured":"Teplizumab [package insert]. Bridgewater: Provention Bio, Inc.; 2023."},{"issue":"4","key":"2150_CR55","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1365-2125.2009.03502.x","volume":"68","author":"EA Dubois","year":"2009","unstructured":"Dubois EA, Cohen AF. Abatacept. Br J Clin Pharmacol. 2009;68(4):480\u20131.","journal-title":"Br J Clin Pharmacol"},{"issue":"9789","key":"2150_CR56","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","volume":"378","author":"T Orban","year":"2011","unstructured":"Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):412\u20139.","journal-title":"Lancet"},{"issue":"5","key":"2150_CR57","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2337\/dc22-2200","volume":"46","author":"WE Russell","year":"2023","unstructured":"Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, et al. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial. Diabetes Care. 2023;46(5):1005\u201313.","journal-title":"Diabetes Care"},{"issue":"1","key":"2150_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2165\/00063030-200620010-00004","volume":"20","author":"PS Hervey","year":"2006","unstructured":"Hervey PS, Keam SJ. Abatacept. BioDrugs. 2006;20(1):53\u201361.","journal-title":"BioDrugs"},{"issue":"11","key":"2150_CR59","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.2337\/db14-0365","volume":"63","author":"S Arif","year":"2014","unstructured":"Arif S, Leete P, Nguyen V, Marks K, Nor NM, Estorninho M, et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes. 2014;63(11):3835\u201345.","journal-title":"Diabetes"},{"issue":"1 Suppl 2","key":"2150_CR60","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30156","volume":"29","author":"DG Maloney","year":"2002","unstructured":"Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29(1 Suppl 2):2\u20139.","journal-title":"Semin Oncol"},{"key":"2150_CR61","unstructured":"Hanif NAF. Rituximab. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2024."},{"issue":"2","key":"2150_CR62","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2337\/dc13-0626","volume":"37","author":"MD Pescovitz","year":"2014","unstructured":"Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, et al. B-lymphocyte depletion with rituximab and \u03b2-cell function: two-year results. Diabetes Care. 2014;37(2):453\u20139.","journal-title":"Diabetes Care"},{"issue":"22","key":"2150_CR63","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","volume":"361","author":"MD Pescovitz","year":"2009","unstructured":"Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143\u201352.","journal-title":"N Engl J Med"},{"issue":"4","key":"2150_CR64","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/cc11304","volume":"16","author":"PM Kasi","year":"2012","unstructured":"Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: serious adverse events associated with the use of rituximab\u2014a critical care perspective. Crit Care. 2012;16(4):231.","journal-title":"Crit Care"},{"key":"2150_CR65","unstructured":"ClinicalTrials.gov USNLoM. Rituximab-pvvr and abatacept vs rituximab-pvvr alone in new onset type 1 diabetes (TN25). https:\/\/clinicaltrials.gov\/study\/NCT03929601. Accessed 11 Oct 2024."},{"issue":"12","key":"2150_CR66","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843\u201362.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2150_CR67","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2150_CR68","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/db16-1250","volume":"66","author":"PM Trivedi","year":"2017","unstructured":"Trivedi PM, Graham KL, Scott NA, Jenkins MR, Majaw S, Sutherland RM, et al. Repurposed JAK1\/JAK2 inhibitor reverses established autoimmune insulitis in NOD mice. Diabetes. 2017;66(6):1650\u201360.","journal-title":"Diabetes"},{"issue":"23","key":"2150_CR69","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","volume":"389","author":"M Waibel","year":"2023","unstructured":"Waibel M, Wentworth JM, So M, Couper JJ, Cameron FJ, MacIsaac RJ, et al. Baricitinib and \u03b2-cell function in patients with new-onset type 1 diabetes. N Engl J Med. 2023;389(23):2140\u201350.","journal-title":"N Engl J Med"},{"key":"2150_CR70","unstructured":"ClinicalTrials.gov USNLoM. Janus kinase (JAK) inhibitors to preserve c-peptide production in new onset type 1 diabetes (T1D). https:\/\/clinicaltrials.gov\/study\/NCT05743244. Accessed 27 Sept 2004."},{"issue":"3","key":"2150_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1122","volume":"9","author":"J Lu","year":"2020","unstructured":"Lu J, Liu J, Li L, Lan Y, Liang Y. Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets. Clin Transl Immunol. 2020;9(3): e1122.","journal-title":"Clin Transl Immunol."},{"issue":"7","key":"2150_CR72","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2337\/dc09-0054","volume":"32","author":"L Mastrandrea","year":"2009","unstructured":"Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care. 2009;32(7):1244\u20139.","journal-title":"Diabetes Care"},{"issue":"21","key":"2150_CR73","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","volume":"383","author":"T Quattrin","year":"2020","unstructured":"Quattrin T, Haller MJ, Steck AK, Felner EI, Li Y, Xia Y, et al. Golimumab and beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med. 2020;383(21):2007\u201317.","journal-title":"N Engl J Med"},{"issue":"9881","key":"2150_CR74","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/S0140-6736(13)60023-9","volume":"381","author":"A Moran","year":"2013","unstructured":"Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381(9881):1905\u201315.","journal-title":"Lancet"},{"key":"2150_CR75","unstructured":"ClinicalTrials.gov USNLoM. Ixekizumab diabetes intervention trial (I-DIT) (I-DIT). https:\/\/clinicaltrials.gov\/study\/NCT04589325. Accessed 2 Oct 2024."},{"key":"2150_CR76","doi-asserted-by":"crossref","unstructured":"Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, et al. IL-6 receptor blockade does not slow \u03b2 cell loss in new-onset type 1 diabetes. JCI Insight. 2021;6(21):e150074.","DOI":"10.1172\/jci.insight.150074"},{"issue":"9","key":"2150_CR77","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1038\/s41591-024-03115-2","volume":"30","author":"D Tatovic","year":"2024","unstructured":"Tatovic D, Marwaha A, Taylor P, Hanna SJ, Carter K, Cheung WY, et al. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nat Med. 2024;30(9):2657\u201366.","journal-title":"Nat Med"},{"issue":"3","key":"2150_CR78","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","volume":"50","author":"HT Idriss","year":"2000","unstructured":"Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 2000;50(3):184\u201395.","journal-title":"Microsc Res Tech"},{"issue":"5","key":"2150_CR79","first-page":"CD004525","volume":"2013","author":"A Lethaby","year":"2013","unstructured":"Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2013;2013(5):CD004525.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2150_CR80","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/ijms19030768","volume":"19","author":"H Lim","year":"2018","unstructured":"Lim H, Lee SH, Lee HT, Lee JU, Son JY, Shin W, et al. Structural biology of the TNF\u03b1 antagonists used in the treatment of rheumatoid arthritis. Int J Mol Sci. 2018;19(3):768.","journal-title":"Int J Mol Sci"},{"key":"2150_CR81","unstructured":"Gerriets V, Goyal A, Khaddour K. Tumor necrosis factor inhibitors. StatPearls. Treasure Island: StatPearls Publishing; 2024."},{"issue":"3","key":"2150_CR82","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1084\/jem.180.3.995","volume":"180","author":"XD Yang","year":"1994","unstructured":"Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med. 1994;180(3):995\u20131004.","journal-title":"J Exp Med"},{"key":"2150_CR83","unstructured":"Tucker ME. Golimumab Preserves Insulin Production in Type 1 Diabetes. 2020. https:\/\/www.medscape.com\/viewarticle\/941224#vp_2. Accessed 4 Nov 2024."},{"key":"2150_CR84","unstructured":"Byrne J. Biosimilar producer looking to get first to market advantage in China and Europe. 2021. https:\/\/www.biopharma-reporter.com\/Article\/2021\/06\/23\/Biosimilar-producer-looking-to-get-first-to-market-advantage-in-China-and-Europe. Accessed 4 Nov 2024."},{"key":"2150_CR85","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.molimm.2018.11.007","volume":"105","author":"Z Zheng","year":"2019","unstructured":"Zheng Z, Zheng F. A complex auxiliary: IL-17\/Th17 signaling during type 1 diabetes progression. Mol Immunol. 2019;105:16\u201331.","journal-title":"Mol Immunol"},{"key":"2150_CR86","unstructured":"M C, AK K. Ustekinumab. StatPearls. Treasure Island: StatPearls Publishing; 2024."},{"key":"2150_CR87","doi-asserted-by":"crossref","unstructured":"Group DPT-TDS. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1685\u201391.","DOI":"10.1056\/NEJMoa012350"},{"issue":"4","key":"2150_CR88","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.diabet.2009.02.005","volume":"35","author":"E Vandemeulebroucke","year":"2009","unstructured":"Vandemeulebroucke E, Gorus FK, Decochez K, Weets I, Keymeulen B, De Block C, et al. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab. 2009;35(4):319\u201327.","journal-title":"Diabetes Metab"},{"issue":"14","key":"2150_CR89","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1056\/NEJM200210033471415","volume":"347","author":"JC Carel","year":"2002","unstructured":"Carel JC, Landais P, Bougn\u00e8res P. Therapy to prevent type 1 diabetes mellitus. N Engl J Med. 2002;347(14):1115\u20136.","journal-title":"N Engl J Med"},{"issue":"5","key":"2150_CR90","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2337\/diacare.28.5.1068","volume":"28","author":"JS Skyler","year":"2005","unstructured":"Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care. 2005;28(5):1068\u201376.","journal-title":"Diabetes Care"},{"issue":"19","key":"2150_CR91","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2017.17070","volume":"318","author":"JP Krischer","year":"2017","unstructured":"Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ, Group WCftTDTOIS. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA. 2017;318(19):1891\u2013902.","journal-title":"JAMA"},{"issue":"9651","key":"2150_CR92","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/S0140-6736(08)61309-4","volume":"372","author":"K N\u00e4nt\u00f6-Salonen","year":"2008","unstructured":"N\u00e4nt\u00f6-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008;372(9651):1746\u201355.","journal-title":"Lancet"},{"key":"2150_CR93","unstructured":"Team PE. ADC 2018: update on the intranasal insulin trial II (INIT II) to prevent type 1 diabetes. PracticeUpdate: Diabetes. 2018 [cited September 27, 2024]. Available from: https:\/\/www.practiceupdate.com\/content\/adc-2018-update-on-the-intranasal-insulin-trial-ii-init-ii-to-prevent-type-1-diabetes\/73021."},{"issue":"3","key":"2150_CR94","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/pedi.12611","volume":"19","author":"H Elding Larsson","year":"2018","unstructured":"Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J, Group D-IS. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial. Pediatr Diabetes. 2018;19(3):410\u20139.","journal-title":"Pediatr Diabetes"},{"issue":"9229","key":"2150_CR95","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(00)02579-4","volume":"356","author":"L Chaillous","year":"2000","unstructured":"Chaillous L, Lef\u00e8vre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diab\u00e8te Insuline Orale group. Lancet. 2000;356(9229):545\u20139.","journal-title":"Lancet"},{"issue":"8","key":"2150_CR96","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1007\/s001250051482","volume":"43","author":"P Pozzilli","year":"2000","unstructured":"Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crin\u00f2 A, et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia. 2000;43(8):1000\u20134.","journal-title":"Diabetologia"},{"key":"2150_CR97","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1196\/annals.1309.057","volume":"1029","author":"B Ergun-Longmire","year":"2004","unstructured":"Ergun-Longmire B, Marker J, Zeidler A, Rapaport R, Raskin P, Bode B, et al. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann NY Acad Sci. 2004;1029:260\u201377.","journal-title":"Ann NY Acad Sci"},{"issue":"9788","key":"2150_CR98","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","volume":"378","author":"DK Wherrett","year":"2011","unstructured":"Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011;378(9788):319\u201327.","journal-title":"Lancet"},{"issue":"4","key":"2150_CR99","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jaut.2009.10.005","volume":"34","author":"T Orban","year":"2010","unstructured":"Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun. 2010;34(4):408\u201315.","journal-title":"J Autoimmun"},{"issue":"7","key":"2150_CR100","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.2337\/dc21-0318","volume":"44","author":"J Ludvigsson","year":"2021","unstructured":"Ludvigsson J, Sumnik Z, Pelikanova T, Nattero Chavez L, Lundberg E, Rica I, et al. Intralymphatic glutamic acid decarboxylase with vitamin D supplementation in recent-onset type 1 diabetes: a double-blind, randomized, placebo-controlled phase IIb trial. Diabetes Care. 2021;44(7):1604\u201312.","journal-title":"Diabetes Care"},{"issue":"7","key":"2150_CR101","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2337\/dbi19-0022","volume":"69","author":"EA James","year":"2020","unstructured":"James EA, Mallone R, Kent SC, DiLorenzo TP. T-cell epitopes and neo-epitopes in type 1 diabetes: a comprehensive update and reappraisal. Diabetes. 2020;69(7):1311\u201335.","journal-title":"Diabetes"},{"issue":"1","key":"2150_CR102","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.diabres.2011.09.019","volume":"95","author":"Y Guan","year":"2012","unstructured":"Guan Y, Zhang M, Li Y, Cao W, Ji M, Liu Y. Vaccination with IA-2 autoantigen can prevent late prediabetic nonobese diabetic mice from developing diabetes mellitus. Diabetes Res Clin Pract. 2012;95(1):93\u20137.","journal-title":"Diabetes Res Clin Pract"},{"key":"2150_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtemb.2022.127040","volume":"73","author":"X Zhang","year":"2022","unstructured":"Zhang X, Dong Y, Liu D, Yang L, Xu J, Wang Q. Antigen-specific immunotherapies in type 1 diabetes. J Trace Elem Med Biol. 2022;73: 127040.","journal-title":"J Trace Elem Med Biol"},{"issue":"6","key":"2150_CR104","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2337\/diab.40.6.709","volume":"40","author":"R Ziegler","year":"1991","unstructured":"Ziegler R, Alper CA, Awdeh ZL, Castano L, Brink SJ, Soeldner JS, et al. Specific association of HLA-DR4 with increased prevalence and level of insulin autoantibodies in first-degree relatives of patients with type I diabetes. Diabetes. 1991;40(6):709\u201314.","journal-title":"Diabetes"},{"issue":"9","key":"2150_CR105","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.4049\/jimmunol.1301902","volume":"193","author":"KA McLaughlin","year":"2014","unstructured":"McLaughlin KA, Gulati K, Richardson CC, Morgan D, Bodansky HJ, Feltbower RG, et al. HLA-DR4-associated T and B cell responses to specific determinants on the IA-2 autoantigen in type 1 diabetes. J Immunol. 2014;193(9):4448\u201356.","journal-title":"J Immunol"},{"issue":"191","key":"2150_CR106","doi-asserted-by":"publisher","first-page":"191ra82","DOI":"10.1126\/scitranslmed.3006103","volume":"5","author":"BO Roep","year":"2013","unstructured":"Roep BO, Solvason N, Gottlieb PA, Abreu JRF, Harrison LC, Eisenbarth GS, et al. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8\u207a T cells in type 1 diabetes. Sci Transl Med. 2013;5(191):191ra82.","journal-title":"Sci Transl Med"},{"issue":"2","key":"2150_CR107","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1365-2249.2008.03814.x","volume":"155","author":"SL Thrower","year":"2009","unstructured":"Thrower SL, James L, Hall W, Green KM, Arif S, Allen JS, et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol. 2009;155(2):156\u201365.","journal-title":"Clin Exp Immunol"},{"key":"2150_CR108","doi-asserted-by":"crossref","unstructured":"Alhadj Ali M, Liu YF, Arif S, Tatovic D, Shariff H, Gibson VB, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med. 2017;9(402):eaaf7779.","DOI":"10.1126\/scitranslmed.aaf7779"},{"key":"2150_CR109","unstructured":"ClinicalTrials.gov USNLoM. A multiple ascending dose trial investigating safety, tolerability and pharmacokinetics of NNC0361-0041 (TOPPLE T1D). https:\/\/clinicaltrials.gov\/study\/NCT04279613. Accessed 27 Sept 2024."},{"key":"2150_CR110","unstructured":"ClinicalTrials.gov USNLoM. A Phase III study to investigate if the study drug diamyd can preserve insulin production and improve glycemic control in patients newly diagnosed with type 1 diabetes (DIAGNODE-3). https:\/\/clinicaltrials.gov\/study\/NCT05018585. Accessed 2 Oct 2024."},{"key":"2150_CR111","unstructured":"ClinicalTrials.gov USNLoM. Study to evaluate the safety and feasibility of Diamyd\u00ae in individuals at risk for type 1 diabetes. https:\/\/clinicaltrials.gov\/study\/NCT05683990. Accessed 2 Oct 2024."},{"issue":"1","key":"2150_CR112","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13287-022-02941-w","volume":"13","author":"M Izadi","year":"2022","unstructured":"Izadi M, Sadr Hashemi Nejad A, Moazenchi M, Masoumi S, Rabbani A, Kompani F, et al. Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I\/II randomized placebo-controlled clinical trial. Stem Cell Res Ther. 2022;13(1):264.","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"2150_CR113","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/dom.14723","volume":"24","author":"M Zieli\u0144ski","year":"2022","unstructured":"Zieli\u0144ski M, \u017bali\u0144ska M, Iwaszkiewicz-Grze\u015b D, Gliwi\u0144ski M, Hennig M, Ja\u017awi\u0144ska-Cury\u0142\u0142o A, et al. Combined therapy with CD4+ CD25highCD127- T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: randomized phase I\/II trial. Diabetes Obes Metab. 2022;24(8):1534\u201343.","journal-title":"Diabetes Obes Metab"},{"issue":"746","key":"2150_CR114","doi-asserted-by":"publisher","first-page":"eadn2404","DOI":"10.1126\/scitranslmed.adn2404","volume":"16","author":"C Bender","year":"2024","unstructured":"Bender C, Wiedeman AE, Hu A, Ylescupidez A, Sietsema WK, Herold KC, et al. A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes. Sci Transl Med. 2024;16(746):eadn2404.","journal-title":"Sci Transl Med."},{"issue":"2","key":"2150_CR115","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2337\/db14-0656","volume":"64","author":"PO Carlsson","year":"2015","unstructured":"Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved \u03b2-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 2015;64(2):587\u201392.","journal-title":"Diabetes"},{"issue":"10","key":"2150_CR116","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.4049\/jimmunol.1601118","volume":"197","author":"A Visperas","year":"2016","unstructured":"Visperas A, Vignali DA. Are regulatory t cells defective in type 1 diabetes and can we fix them? J Immunol. 2016;197(10):3762\u201370.","journal-title":"J Immunol"},{"key":"2150_CR117","unstructured":"ClinicalTrials.gov USNLoM. Safety and Efficacy of CELZ-201 in patients with recent onset type 1 diabetes (CREATE-1). https:\/\/clinicaltrials.gov\/study\/NCT05626712. Accessed 2 Oct 2024."},{"key":"2150_CR118","doi-asserted-by":"crossref","unstructured":"Uenishi GI, Repic M, Yam JY, Landuyt A, Saikumar-Lakshmi P, Guo T, et al. GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes. JCI Insight. 2024;9(6):e171844.","DOI":"10.1172\/jci.insight.171844"},{"issue":"1","key":"2150_CR119","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/0963689717742819","volume":"27","author":"M Magatti","year":"2018","unstructured":"Magatti M, Vertua E, Cargnoni A, Silini A, Parolini O. The immunomodulatory properties of amniotic cells: the two sides of the coin. Cell Transplant. 2018;27(1):31\u201344.","journal-title":"Cell Transplant"},{"issue":"15","key":"2150_CR120","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1001\/jama.2009.470","volume":"301","author":"CE Couri","year":"2009","unstructured":"Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301(15):1573\u20139.","journal-title":"JAMA"},{"issue":"8","key":"2150_CR121","first-page":"611","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A. FDA approves first cell therapy for type 1 diabetes. Nat Rev Drug Discov. 2023;22(8):611.","journal-title":"Nat Rev Drug Discov"},{"key":"2150_CR122","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.941918","volume":"29","author":"DV Parums","year":"2023","unstructured":"Parums DV. Editorial: first regulatory approval for allogeneic pancreatic islet beta cell infusion for adult patients with type 1 diabetes mellitus. Med Sci Monit. 2023;29: e941918.","journal-title":"Med Sci Monit"},{"issue":"4","key":"2150_CR123","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJM200007273430401","volume":"343","author":"AM Shapiro","year":"2000","unstructured":"Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230\u20138.","journal-title":"N Engl J Med"},{"issue":"22","key":"2150_CR124","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1016\/j.cell.2024.09.004","volume":"187","author":"S Wang","year":"2024","unstructured":"Wang S, Du Y, Zhang B, Meng G, Liu Z, Liew SY, et al. Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell. 2024;187(22):6152-64.e18.","journal-title":"Cell"},{"key":"2150_CR125","unstructured":"Keith N. Sana Biotechnology announces positive clinical results from type 1 diabetes study of islet cell transplantation without immunosuppression. 2025. https:\/\/ir.sana.com\/news-releases\/news-release-details\/sana-biotechnology-announces-positive-clinical-results-type-1. Accessed 9 Jan 2025."},{"issue":"9","key":"2150_CR126","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00125-024-06205-5","volume":"67","author":"M Phillip","year":"2024","unstructured":"Phillip M, Achenbach P, Addala A, Albanese-O\u2019Neill A, Battelino T, Bell KJ, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia. 2024;67(9):1731\u201359.","journal-title":"Diabetologia"},{"key":"2150_CR127","doi-asserted-by":"crossref","unstructured":"Aye T, Boney CM, Orr CJ, Leonard MB, Leslie LK, Allen DB. Child health needs and the pediatric endocrinology workforce: 2020\u20132040. Pediatrics. 2024;153(Suppl 2):e2023063678J.","DOI":"10.1542\/peds.2023-063678J"},{"issue":"11","key":"2150_CR128","first-page":"1399","volume":"26","author":"JC Simeone","year":"2020","unstructured":"Simeone JC, Shah S, Ganz ML, Sullivan S, Koralova A, LeGrand J, et al. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States. J Manag Care Spec Pharm. 2020;26(11):1399\u2013410.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"2150_CR129","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1089\/dia.2021.0329","volume":"24","author":"HV Nguyen","year":"2022","unstructured":"Nguyen HV, Schatz DA, Mital S, Jacobsen LM, Haller MJ. Cost-effectiveness of low-dose antithymocyte globulin versus other immunotherapies for treatment of new-onset type 1 diabetes. Diabetes Technol Ther. 2022;24(4):258\u201367.","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"2150_CR130","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4103\/0253-7613.103235","volume":"44","author":"S Chandrashekara","year":"2012","unstructured":"Chandrashekara S. The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. Indian J Pharmacol. 2012;44(6):665\u201371.","journal-title":"Indian J Pharmacol."},{"issue":"8","key":"2150_CR131","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1089\/dia.2019.0444","volume":"22","author":"RL DiSantostefano","year":"2020","unstructured":"DiSantostefano RL, Sutphin J, Hedrick JA, Klein K, Mansfield C. Parent preferences for delaying insulin dependence in children at risk of stage III type 1 diabetes. Diabetes Technol Ther. 2020;22(8):584\u201393.","journal-title":"Diabetes Technol Ther"},{"issue":"Suppl 1","key":"2150_CR132","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.2337\/dc24-S003","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S43\u201351.","journal-title":"Diabetes Care"},{"issue":"8","key":"2150_CR133","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1172\/JCI81722","volume":"125","author":"MR Rigby","year":"2015","unstructured":"Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125(8):3285\u201396.","journal-title":"J Clin Invest"},{"key":"2150_CR134","unstructured":"ClinicalTrials.gov USNLoM. FrexalimAB in preservation of endogenous insULIN secretion compared to placebo in adUlts and adolescents on top of inSulin therapy (FABULINUS). https:\/\/clinicaltrials.gov\/study\/NCT06111586. Accessed 2 Oct 2024."},{"key":"2150_CR135","unstructured":"ClinicalTrials.gov USNLoM. Hydroxychloroquine in individuals at-risk for type 1 diabetes mellitus (TN-22). https:\/\/www.clinicaltrials.gov\/study\/NCT03428945. Accessed 2 Oct 2024."},{"key":"2150_CR136","unstructured":"ClinicalTrials.gov USNLoM. Study of safety and efficacy of CFZ533 in type 1 diabetes pediatric and young adult subjects (CCFZ533X2207). https:\/\/clinicaltrials.gov\/study\/NCT04129528. Accessed 27 Sept 2024."},{"key":"2150_CR137","doi-asserted-by":"crossref","unstructured":"Cabrera-Rode E, Cubas-Due\u00f1as I, Rodr\u00edguez-Acosta J, Garc\u00eda-Garc\u00eda Y, Torres-L\u00f3pez Y, Prieto-Noa C, et al. An exploratory study of itolizumab on the preservation of beta cell function in adults with recent-onset type 1 diabetes. J Clin Med. 2022;11(7):1789.","DOI":"10.3390\/jcm11071789"},{"issue":"9","key":"2150_CR138","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s001250051028","volume":"41","author":"R Coutant","year":"1998","unstructured":"Coutant R, Landais P, Rosilio M, Johnsen C, Lahlou N, Chatelain P, et al. Low dose linomide in type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia. 1998;41(9):1040\u20136.","journal-title":"Diabetologia"},{"issue":"4","key":"2150_CR139","doi-asserted-by":"publisher","first-page":"826","DOI":"10.2337\/dc09-1349","volume":"33","author":"PA Gottlieb","year":"2010","unstructured":"Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care. 2010;33(4):826\u201332.","journal-title":"Diabetes Care"},{"key":"2150_CR140","unstructured":"ClinicalTrials.gov USNLoM. Siplizumab in T1DM (DESIGNATE). https:\/\/clinicaltrials.gov\/study\/NCT05574335. Accessed 27 Sept 2024."},{"key":"2150_CR141","unstructured":"ClinicalTrials.gov USNLoM. A phase 2, randomized, placebo controlled study investigating the efficacy and safety of sorafenib in new-onset type 1 diabetes mellitus. https:\/\/clinicaltrials.gov\/study\/NCT06227221. Accessed 2 Oct 2024."},{"issue":"7","key":"2150_CR142","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603\u201313.","journal-title":"N Engl J Med"},{"key":"2150_CR143","doi-asserted-by":"publisher","first-page":"49","DOI":"10.12688\/wellcomeopenres.15697.1","volume":"5","author":"ML Marcovecchio","year":"2020","unstructured":"Marcovecchio ML, Wicker LS, Dunger DB, Dutton SJ, Kopijasz S, Scudder C, et al. Interleukin-2 therapy of autoimmunity in diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial. Wellcome Open Res. 2020;5:49.","journal-title":"Wellcome Open Res."},{"key":"2150_CR144","unstructured":"ClinicalTrials.gov USNLoM. An immunotherapy vaccine (PIpepTolDC) for the treatment of patients with type 1 diabetes. https:\/\/clinicaltrials.gov\/study\/NCT04590872. Accessed 2 Oct 2024."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02150-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02150-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02150-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T03:36:56Z","timestamp":1743478616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02150-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":144,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2150"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02150-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"13 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review was performed with the support of the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers K23DK131363, P01AI042288, and K12DK133995. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MJH is a consultant for Sanofi, GentiBio, and MannKind and is on the scientific advisory board of SAB BIO. TPF and BSB have no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data analyzed to support our conclusions are included in this publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code available"}},{"value":"TPF drafted and edited the initial and final versions of the manuscript, tables, and figures. MJH conceived the review and edited the manuscript. BSB drafted and edited the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}